Fluent BioSciences, a cutting-edge life sciences firm main the cost in revolutionizing single-cell evaluation by means of easy, cost-effective, and extremely scalable single-cell RNA sequencing options is thrilled to announce the award of an NIH Small Enterprise Innovation Analysis (SBIR) Section II grant, funded by the Nationwide Institute of Normal Medical Sciences (NIGMS, 2 R44 GM137648). This funding will assist the commercialization of million-cell evaluation kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
Prototype million-cell PIPseq kits developed by Fluent BioSciences that allow the profiling of an unprecedented variety of cells inside a single response had been lately examined within the laboratory of Samantha Morris at Washington College, St. Louis (WUSTL). The WUSTL staff employs single-cell lineage tracing to interrogate easy methods to recreate physiologically correct cell varieties with mobile reprogramming. Ultima Genomics sequencing of the prototype million-cell PIPseq information revealed clonal lineage timber with restriction of particular cell reprogramming fates. Leveraging the unequalled scalability of PIPseq with the reasonably priced high-capacity sequencing of Ultima Genomics, WUSTL demonstrated that mobile reprogramming research may be simply and affordably carried out at scale. “Pattern preparation was easy and the size of the million-cell equipment supplied spectacular energy to our single-cell lineage tracing observations,” stated Samantha Morris, Affiliate Professor at WUSTL.
“The collaboration between Fluent BioSciences and Ultima represents a outstanding synergy in pushing the boundaries of single-cell evaluation,” stated Brian McKernan, CEO of Fluent BioSciences. “This collaboration harnesses the strengths and experience of each corporations to handle a vital problem confronted by researchers – the flexibility to carry out single-cell sequencing on bigger cell inputs for improved scalability and decreased value. By eliminating the necessity for microfluidics units or chips, the PIPseq know-how provides unparalleled flexibility within the scale of beads per pattern.”
“We’re excited to work with Fluent BioSciences to display compatibility of PIPseq on Ultima sequencers, optimize library development for Ultima-specific sequencing, and display high-capacity single cell evaluation throughout a number of functions developed by Fluent, together with excessive cell enter neuroscience, multi-sample hashing, and complicated CRISPR modifying functions. “The only-cell market is present process one other main wave of development with larger-scale experiments enabled by low-cost sequencing and development of single-cell know-how”, stated Doron Lipson, CSO of Ultima Genomics.
By way of this partnership, Fluent BioSciences and Ultima purpose to revolutionize the sphere of single-cell evaluation by enabling researchers to unlock deeper insights into mobile mechanisms and illness pathways with unparalleled throughput and accuracy.